Search results
Results from the WOW.Com Content Network
Alendronic acid is indicated for the treatment and prevention of osteoporosis in postmenopausal women; [3] the treatment to increase bone mass in men with osteoporosis; [3] the treatment of glucocorticoid-induced osteoporosis; [3] and the treatment of Paget's disease of bone. [3] [4]
Alendronic acid/colecalciferol, sold under the brand name Fosamax Plus D among others, is a medication for the treatment of osteoporosis in men or in postmenopausal women. [3] [2] [4] [6] Alendronic acid/colecalciferol was approved for use in the United States and in the European Union in 2005. [7] [5]
Bisphosphonates are used to treat osteoporosis, osteitis deformans (Paget's disease of the bone), bone metastasis (with or without hypercalcemia), multiple myeloma, and other conditions involving fragile, breakable bone. In osteoporosis and Paget's, the most popular first-line bisphosphonate drugs are alendronate and risedronate.
About 22 million women and 5.5 million men in the European Union had osteoporosis in 2010. [15] In the United States in 2010, about 8 million women and between 1 and 2 million men had osteoporosis. [13] [16] White and Asian people are at greater risk. [3] The word "osteoporosis" is from the Greek terms for "porous bones". [17]
Ibandronic acid is a bisphosphonate medication used in the prevention and treatment of osteoporosis and metastasis-associated skeletal fractures in people with cancer. [4] It may also be used to treat hypercalcemia (elevated blood calcium levels).
Primary, or involuntary osteoporosis, can further be classified into Type I or Type II. [1] Type I refers to postmenopausal osteoporosis and is caused by the deficiency of estrogen. [1] While senile osteoporosis is categorized as an involuntary, Type II, and primary osteoporosis, which affects both men and women over the age of 70 years.
It was approved for prevention and treatment of osteoporosis and was the first clinically available SERM to prevent both osteoporosis and breast cancer. [7] Ospemifene was approved on February 26, 2013, for the treatment of moderate to severe dyspareunia , which is a symptom, due to menopause , of vulvar and vaginal atrophy .
Osteoporosis, a skeletal disorder characterized by compromised bone strength and increased risk of fractures, is a major concern in bone health, particularly among older adults. [ 2 ] [ 3 ] Maintaining good bone health involves a combination of adequate calcium and vitamin D intake, regular weight-bearing exercise, and avoiding risk factors ...